8-K: DBV Technologies Launches $150M At-The-Market Equity Program

DBV Technologies has established a new At-The-Market equity offering program to raise up to $150 million through the sale of American Depositary Shares.

Summary

• DBV Technologies S.A. entered into a sales agreement with Citizens JMP Securities, LLC for an At-The-Market (ATM) equity offering program.
• The company may offer and sell American Depositary Shares (ADSs), each representing five ordinary shares, with an aggregate offering price of up to $150.0 million.
• Sales will be conducted from time to time through Citizens JMP Securities, LLC as the sales agent, using commercially reasonable efforts.
• The company will pay Citizens JMP Securities, LLC a commission equal to 3.0% of the gross sales price per ADS sold.
• Proceeds are primarily intended for activities associated with the Biologics License Application (BLA), potential approval and launch of VIASKIN Peanut patch in toddlers aged 1-3 years old, advancing product candidates using the VIASKIN platform, and for working capital and other general corporate purposes.
• The program is subject to French regulatory limits, including that the number of underlying ordinary shares issued over a 12-month rolling period must represent less than 30% of the total number of ordinary shares already admitted to trading on Euronext Paris without a French listing prospectus.
• The issuance is authorized by the 25th and 31st resolutions of the company's combined general shareholders meeting held on June 11, 2025.
• The new ATM program replaces a prior sales agreement dated May 2, 2022, which has been terminated, with similar terms and conditions.

Sentiment

Score: 6

Explanation: The establishment of the ATM program provides crucial funding for the company's key development and regulatory milestones, which is a positive for a clinical-stage biopharmaceutical company. However, it also introduces potential dilution for existing shareholders, leading to a neutral to slightly positive sentiment.

Positives

• Secures up to $150 million in capital, providing funding flexibility for ongoing operations and strategic initiatives.
• Funds are earmarked for critical activities, including the Biologics License Application (BLA) and potential launch of VIASKIN Peanut patch, which are key value drivers.
• Supports the advancement of product candidates utilizing the proprietary VIASKIN technology platform, reinforcing the company's R&D pipeline.
• Provides capital for general corporate purposes and working capital, enhancing financial stability.

Negatives

• The offering introduces potential dilution for existing shareholders, with an illustrative dilution of approximately 50% if the full $150 million is issued.
• There is no assurance that the sales agent will be successful in placing all or any of the ADSs, meaning the full $150 million may not be raised.
• A 3.0% commission on gross sales will reduce the net proceeds received by the company.

Risks

• Market conditions may impact the ability to sell ADSs at favorable prices or to sell the full authorized amount.
• No guarantee of placement means the company may not raise the full $150 million, potentially impacting funding for planned activities.
• French regulatory limits, specifically the 30% rule for shares admitted to trading on Euronext Paris without a French listing prospectus, could restrict the pace or total volume of sales.
• Potential for share price volatility due to the ongoing nature of an At-The-Market offering and the associated dilution.

Future Outlook

The company intends to use the net proceeds from the ATM program to fund activities associated with the Biologics License Application (BLA) and potential launch of VIASKIN Peanut patch in toddlers, advance its product candidates using the VIASKIN platform, and for general corporate purposes. This financing is expected to support the company's ongoing development and regulatory milestones.

Management Comments

• The company intends to use the net proceeds, if any, primarily for activities associated with the Biologics License Application (BLA), potential approval and launch of VIASKIN Peanut patch in toddlers aged 1-3 years old.
• Proceeds will also be used to advance the development of product candidates using the proprietary VIASKIN technology platform, and for working capital and other general corporate purposes, at the company's discretion.

Industry Context

At-The-Market (ATM) equity programs are a common and flexible financing tool in the biopharmaceutical industry, particularly for clinical-stage companies like DBV Technologies. These programs allow companies to raise capital incrementally over time, reducing the immediate market impact often associated with large, underwritten offerings. This approach provides financial flexibility to fund ongoing research and development, clinical trials, and regulatory submissions, which are capital-intensive activities characteristic of the sector.

Comparison to Industry Standards

• At-The-Market (ATM) equity programs are a common and flexible financing tool utilized by clinical-stage biopharmaceutical companies to fund research and development, regulatory submissions, and general corporate needs.
• The 3.0% commission rate payable to the sales agent, Citizens JMP Securities, LLC, is within the typical range for such ATM facilities in the biotechnology sector.
• The program's structure, allowing for opportunistic sales of American Depositary Shares (ADSs) at market prices, aligns with industry practices for companies seeking to manage dilution and market impact.
• Specific French regulatory limits, such as the requirement that underlying ordinary shares issued over a 12-month rolling period represent less than 30% of shares already admitted to trading on Euronext Paris without a French listing prospectus, are unique to French-incorporated entities and are a standard compliance consideration for such companies.

Stakeholder Impact

• Shareholders: Face potential dilution from the issuance of new ADSs but benefit from the company securing capital for critical development and operational activities.
• Employees: Continued funding supports ongoing research, development, and potential commercialization efforts, contributing to job security and project continuity.
• Customers/Patients: The capital raise supports the advancement of the VIASKIN Peanut patch towards potential approval and launch, which could benefit patients with peanut allergies.
• Creditors: Improved financial liquidity and extended cash runway may reduce credit risk.

Next Steps

• Sales of ADSs under the ATM program will occur from time to time, depending on market conditions and company needs.
• The company will include information about its use of the ATM program in its quarterly results publications.
• Updates on each capital increase completed under the ATM program will be provided on the company's corporate website.
• Continued focus on activities associated with the Biologics License Application (BLA) for VIASKIN Peanut patch in toddlers.
• Advancement of product candidates using the VIASKIN platform.

Key Dates

Recommendation

The establishment of a $150 million At-The-Market equity program provides DBV Technologies with crucial funding to advance its Biologics License Application (BLA) for VIASKIN Peanut patch and other product candidates. While this secures capital for key operational and development milestones, it also introduces potential dilution for existing shareholders. For a clinical-stage biopharmaceutical company, securing financing is a necessary step for continued progress, balancing the need for capital with the impact on share structure. The program's flexibility allows the company to raise funds opportunistically, which is a positive, but the lack of guaranteed sales and the potential for market-driven pricing fluctuations warrant a 'hold' stance as investors assess the execution of the program and the progress of its clinical pipeline.

Keywords

DBV Technologies, DBVT, At-The-Market, ATM Program, Equity Offering, Capital Raise, Biopharmaceutical, VIASKIN, Peanut Allergy, Nasdaq, SEC Filing, ADS